Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing
KPC variant
KPC-producing Klebsiella pneumoniae
antimicrobial resistance
ceftazidime-avibactam resistance
imipenem-relebactam
imipenem/cilastatin/relebactam
polymicrobial infections
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2024
2024
Historique:
received:
13
05
2024
accepted:
25
06
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Real-life experience with imipenem/cilastatin/relebactam (IMI/REL) for the treatment of KPC-producing Adult patients with KPC-Kp or DTR-PA infections who received ≥48 h of IMI/REL were included. Clinical and microbiological outcomes were retrieved through the medical records. Primary outcome was clinical cure. Secondary outcomes included mortality from infection onset and adverse effects attributable to IMI/REL. We included 10 patients with different infections caused by DTR-PA ( We reported the preliminary real-life experience on the successful and safe use of IMI/REL for the treatment of KPC-Kp or DTR-PA complicated infections, including pneumonia and bone infections.
Identifiants
pubmed: 39081883
doi: 10.3389/fmicb.2024.1432296
pmc: PMC11286388
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1432296Informations de copyright
Copyright © 2024 Leanza, Mascellino, Volpicelli, Covino, Falletta, Cancelli, Franchi, Carnevalini, Mastroianni and Oliva.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.